Notice: Private records are filtered that would not be displayed.
Sort:
  • PROJ transcriptome of wp2 and wp2-sp2

    mujie zhang, ,2021.12.14

    Description

    OEP002984

  • PROJ Transposable Phages Database

    mujie zhang, ,2022.06.28

    Description

    OEP003495

  • PROJ IP-MS of FLAG-MRG15 in HEK 293T

    Cheng Tian, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences,2022.06.21

    Description

    FLAG-MRG15 was overexpressed in HEK 293T cells, with the cell pellets collected after 48 hours and lysed with RIPA buffer (Millipore, 20188). FLAG-MRG15 was then immunoprecipitated with anti-FLAG M2 Magnetic Beads (Sigma-Aldrich, M8823) at 4 °C overnight. The M2 beads were washed with RIPA buffer (Millipore, 20188) for three times, and binding proteins were eluted with 3× FLAG peptide (Sigma-Aldrich, F4799). The eluate from M2 beads was subjected to mass spectrometry analysis.

    OEP003465

  • PROJ WES data for 4 Yunnan minorities

    Shuhua Xu, PICB,2021.08.06

    Description

    This project is to investigate the genetic structure, population demography and adaptive evolution by analyzing the whole-exome sequences of 242 Western Yunnan minorities, including 65 Achang, 52 Dai, 65 Deang, and 60 Jingpo.

    OEP002587

  • PROJ WGS of Hainan Li

    Shuhua Xu, PICB,2022.02.22

    Description

    Li people are the largest group of aboriginal islanders of China but remain under-investigated in both anthropology and genetics. We make the first whole-genome sequencing effort to gain insights into ancestral origins and evolutionary history of this islander group (HNL).

    OEP003168

  • PROJ JZ202005211831

    support scnode, ,2022.04.21

    Description

    Mouse Single-Cell Samples Collected by Shanghai General Hospital

    OEP003311

  • PROJ Pancreatic ductal adenocarcinoma adjuvant chemotherapy vulnerability: a prospective observational study

    Chenxu Gao, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital,2023.04.11

    Description

    A prospective observational study enrolled 1,171 PDAC patients who had pancreatectomy is reported. After substantive follow-up and proteomic profiling of 191 patient samples, we identify functional modules with clinical relevance, establish a proteomic-level prognostic risk model for PDAC, and cross-validate the model using external as well as independent in-house cohorts. Two new biomarkers, indicative of PDAC adjuvant chemotherapy sensitivity, are discovered using integrated analysis of both clinical and proteomic datasets. Our prospective evidence points us towards a subgroup of patients to whom mild adjuvant chemo plan (for example S-1) might provide overall survival benefit.

    OEP004100

  • PROJ multi-omics analyses for KRAS/Lkb1 mouse tumors and organoids

    Hongjun Li, Tsinghua University,2023.04.05

    Description

    For bulk RNA-seq, the plastic organoids and non-plastic organoids derived from KDL mouse model at early passages were collected. For bulk ATAC-seq, the time-series plastic organoids derived from KDL mouse model were collected for analysis. For single-cell RNA-seq (scRNA-seq) of KDL live time-series transition organoid cells, the organoid cells from cell culture at passage 1, 3 and 8 were collected for analysis.

    OEP004095

  • PROJ RNAseq and WES glioma tissues and bioprinted counterparts

    Yu Yao, Fudan University,2023.04.05

    Description

    To establish a more clinically relevant model, we developed 3D bioprinted patient-derived glioma tissue (PDT) models. Surgically resected GBM tumor tissues were obtained from glioma patients with different demographic background and disease characteristics. Patient specimens underwent RNA-seq. Two patient specimens and their corresponding PDTs were also subjected to whole exosome sequencing and germline corrected using matched blood samples.

    OEP004093

  • PROJ Combination of decitabine and epitoside is highly effective in treating p53-mutated MDS/AMLmds via activating notch signaling

    Jiexian Ma, Fudan university,2023.04.01

    Description

    To begin to elucidate the mechanism of action of decitabine with etoposide-based(D+E) treatment, we selected the TP53 mutation (THP-1 and U937) and TP53 WT (MOLM13 and OCI ) AML/MDS cell lines and treated them with etoposide and decitabine according to the indicated dose

    OEP004090